# **Data Changes for the CCDD SEPTEMBER Release Candidate 2023**

## **Based on the QA Release Generation** 20230901

|  |  |
| --- | --- |
| Data entered by | A.Raghuveer |
| Data checked by | J. Hutsul |

## **TM File**

### **Deprecation**

The following TM concept(s) needs to be added back into the TM File with a status of **deprecated**. [Reason for deprecation].

|  |  |  |
| --- | --- | --- |
| **tm\_code** | **tm \_formal\_name** | **tm\_status** |
|  | [NONE] | Deprec |

### **Code permanence – name changes**

The following TM concept(s) need to keep its/their existing tm\_code even though their formal name has changed. [Reason for name change].

|  |  |  |
| --- | --- | --- |
| **tm\_code (to keep)** | **tm \_formal\_name** | **tm\_code in QA Release was** |
|  | [NONE] |  |

### **Concept permanence - returns**

The following TM concept(s) is/are “missing” from the QA Release, but should come back ‘automatically’ in the Release Candidate with a status of “inactive”, when its/their supporting NTPs and MPs will be on the “Whitelist”, as their DINs have been Cancelled Post Market or are Dormant.

|  |  |
| --- | --- |
| **tm\_code** | **tm \_formal\_name** |
|  | [NONE] |

## **NTP File**

### **Deprecation**

The following NTP concept(s) needs to be added back into the NTP File with status of **deprecated**.

|  |  |  |  |
| --- | --- | --- | --- |
| **ntp\_code** | **ntp \_formal\_name** | **ntp\_fr\_description** | **ntp\_status** |
| 9000008 | phenytoin 50 mg oral tablet | phénytoïne 50 mg comprimé oral | Deprec |

### **Status update – Inactive**

The following NTP concept(s) are generating as Active but need to be set to **inactive** to align with their respective MPs.

|  |  |  |  |
| --- | --- | --- | --- |
| **ntp\_code** | **ntp \_formal\_name** | **ntp\_fr\_description** | **ntp\_status** |
|  | [NONE] |  | Inactive |

### **Code permanence – name changes**

The following NTP concepts need to keep their existing ntp\_code even though their formal name has changed.

|  |  |  |
| --- | --- | --- |
| **ntp\_code (to keep)** | **ntp \_formal\_name** | **ntp\_code in QA Release was** |
|  | [NONE] |  |

### **Concept permanence – returns check**

The following NTP concepts are “missing” from the QA Release, but should come back ‘automatically’ in the Release Candidate, when their supporting MPs will be on the “Whitelist”, as their DINs have been Cancelled Post Market or are Dormant.

|  |  |
| --- | --- |
| **ntp\_code** | **ntp \_formal\_name** |
| 9002348 | chlorhexidine gluconate 2 % cutaneous gel |
| 9003804 | cyproheptadine hydrochloride 2 mg per 5 mL syrup |
| 9003642 | tazarotene 0.1 % cutaneous cream |

## **MP File**

### **Deprecation (very rare)**

No new deprecated concepts.

### **Deprecation – manual return**

The following MP concepts need to be added back into the MP File with status of **deprecated**. For all DINs, they have had additional UoP added. All products now have new MP.

|  |  |  |  |
| --- | --- | --- | --- |
| **mp\_code** | **mp \_formal\_name** | **mp\_fr\_description** | **mp\_status** |
|  | [NONE] |  | Deprec |

### **Status update – deprecation**

The following MP concepts are generating as active but need to be set to **deprecated**. Some of these products have been assigned a new DIN, others have been discontinued.

|  |  |  |
| --- | --- | --- |
| **mp\_code** | **mp \_formal\_name** | **mp\_status** |
|  | [NONE] | Deprec |

### **Status update – Inactive**

The following MP concepts are generating as active but need to be set to **inactivated**. The DIN is still active but these particular presentations have been discontinued.

|  |  |  |
| --- | --- | --- |
| **mp\_code** | **mp \_formal\_name** | **mp\_status** |
|  | [NONE] | Inactive |

### **DPD descriptors**

The following concept(s) needs to have the DPD descriptor added to the brand name to allow differentiation between duplicate mp\_formal names.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| drug\_  code | mp\_code | mp\_formal\_name | DPD descriptor | DPD descriptor - FR |
|  | [NONE] |  |  |  |

### **Concept permanence – manual return**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| drug\_code | mp\_code | mp\_formal\_name | mp\_fr\_description | CCDD status |
|  | [NONE] |  |  |  |

### **Concept permanence – returns check**

The following MPs need to be added to the Inclusion list to make sure that they (and their associated NTPs/TMs) continue to be present in the release:

|  |  |  |  |
| --- | --- | --- | --- |
| **drug\_code** | **mp\_code** | **mp\_formal\_name** | **DPD status** |
| 19941 | 2164426 | ACEBUTOLOL - 400 (acebutolol (acebutolol hydrochloride) 400 mg oral tablet) PRO DOC LIMITEE | Canceled post-market Expiry 2023.08.31 |
| 19939 | 2164396 | ACEBUTOLOL-100 (acebutolol (acebutolol hydrochloride) 100 mg oral tablet) PRO DOC LIMITEE | Canceled post-market Expiry 2023.08.31 |
| 19940 | 2164418 | ACEBUTOLOL-200 (acebutolol (acebutolol hydrochloride) 200 mg oral tablet) PRO DOC LIMITEE | Canceled post-market Expiry 2023.08.31 |
| 78142 | 2296063 | APO-BICALUTAMIDE (bicalutamide 50 mg oral tablet) APOTEX INC | dormant 2023.05.14 |
| 89352 | 2408767 | APO-QUINAPRIL/HCTZ (hydrochlorothiazide 12.5 mg and quinapril (quinapril hydrochloride) 10 mg oral tablet) APOTEX INC | dormant 2023.07.22 |
| 2064 | 13668 | ATASOL FORTE TAB 500MG (acetaminophen 500 mg oral tablet) CHURCH & DWIGHT CANADA CORP | Canceled post-market Expiry 2023.08.31 |
| 99848 | 2509172 | BENDAMUSTINE HYDROCHLORIDE FOR INJECTION (bendamustine hydrochloride 100 mg per vial powder for solution for injection) JAMP PHARMA CORPORATION | dormant 2023.07.31 |
| 96421 | 2474182 | CARBOCAINE 2% WITH NEO-COBEFRIN (corbadrine 0.05 mg per mL and mepivacaine hydrochloride 20 mg per mL solution for injection 1.8 mL cartridge) NOVOCOL PHARMACEUTICAL OF CANADA INC | Canceled post-market Expiry 2023.08.31 |
| 94723 | 2459922 | CCP-CITALOPRAM (citalopram (citalopram hydrobromide) 40 mg oral tablet) CELLCHEM PHARMACEUTICALS INC. | Canceled post-market Expiry 2022.02.28 |
| 19441 | 824143 | DDAVP TABLETS 0.2MG (desmopressin acetate 0.2 mg oral tablet) FERRING INC | Canceled post-market Expiry 2023.08.31 |
| 11826 | 1930079 | GERMI STAT GEL 2% (chlorhexidine gluconate 2 % cutaneous gel) GERMIPHENE CORPORATION | dormant 2023.08.01 |
| 88227 | 2397307 | JAMP PIOGLITAZONE (pioglitazone (pioglitazone hydrochloride) 15 mg oral tablet) JAMP PHARMA CORPORATION | dormant 2023.07.31 |
| 85042 | 2365529 | JAMP PIOGLITAZONE (pioglitazone (pioglitazone hydrochloride) 30 mg oral tablet) JAMP PHARMA CORPORATION | dormant 2023.07.31 |
| 85043 | 2365537 | JAMP PIOGLITAZONE (pioglitazone (pioglitazone hydrochloride) 45 mg oral tablet) JAMP PHARMA CORPORATION | dormant 2023.07.31 |
| 96780 | 2477106 | JAMP ZOLMITRIPTAN (zolmitriptan 2.5 mg oral tablet) JAMP PHARMA CORPORATION | dormant 2023.07.31 |
| 91987 | 2435527 | JAMP-AMITRIPTYLINE TABLETS (amitriptyline hydrochloride 10 mg oral tablet) JAMP PHARMA CORPORATION | dormant 2023.07.31 |
| 91988 | 2435535 | JAMP-AMITRIPTYLINE TABLETS (amitriptyline hydrochloride 25 mg oral tablet) JAMP PHARMA CORPORATION | dormant 2023.07.31 |
| 91989 | 2435543 | JAMP-AMITRIPTYLINE TABLETS (amitriptyline hydrochloride 50 mg oral tablet) JAMP PHARMA CORPORATION | dormant 2023.07.31 |
| 91990 | 2435551 | JAMP-AMITRIPTYLINE TABLETS (amitriptyline hydrochloride 75 mg oral tablet) JAMP PHARMA CORPORATION | dormant 2023.07.31 |
| 76888 | 2283255 | JAMP-DOCUSATE CALCIUM (docusate calcium 240 mg oral capsule) JAMP PHARMA CORPORATION | dormant 2023.07.31 |
| 87663 | 2391287 | JAMP-ROSUVASTATIN (rosuvastatin (rosuvastatin calcium) 40 mg oral tablet) JAMP PHARMA CORPORATION | dormant 2023.07.31 |
| 87660 | 2391252 | JAMP-ROSUVASTATIN (rosuvastatin (rosuvastatin calcium) 5 mg oral tablet) JAMP PHARMA CORPORATION | dormant 2023.07.31 |
| 85360 | 2368625 | JAMP-SOTALOL (sotalol hydrochloride 160 mg oral tablet) JAMP PHARMA CORPORATION | dormant 2023.07.31 |
| 87241 | 2386836 | JAMPOCAINE 5% (lidocaine 5 % cutaneous ointment) JAMP PHARMA CORPORATION | dormant 2023.07.31 |
| 50390 | 2231106 | MICOZOLE (miconazole nitrate 2 % vaginal cream) TARO PHARMACEUTICALS INC | Canceled post-market Expiry 2023.07.31 |
| 99519 | 2505819 | MINT-LEVOFLOXACIN (levofloxacin (levofloxacin hemihydrate) 500 mg oral tablet) MINT PHARMACEUTICALS INC | dormant 2023.08.17 |
| 99518 | 2505800 | MINT-LEVOFLOXACIN (levofloxacin (levofloxacin hemihydrate) 750 mg oral tablet) MINT PHARMACEUTICALS INC | dormant 2023.08.11 |
| 83597 | 2350769 | NAPROXEN (naproxen 375 mg oral tablet) SANIS HEALTH INC | Canceled post-market Expiry 2023.08.31 |
| 81376 | 2328232 | PEGALAX (polyethylene glycol 3350 100 % powder for oral solution) ARALEZ PHARMACEUTICALS CANADA INC | Canceled post-market Expiry 2023.06.24 |
| 93454 | 2448807 | PRIVA-SILDENAFIL (sildenafil (sildenafil citrate) 100 mg oral tablet) NORA PHARMA INC | Canceled post-market Expiry 2023.08.31 |
| 84674 | 2361671 | RAPAFLO (silodosin 8 mg oral capsule) ALLERGAN INC | Canceled post-market Expiry 2023.08.31 |
| 80143 | 2315920 | REFRESH REDNESS RELIEF (naphazoline hydrochloride 0.1 % ophthalmic drops) ALLERGAN INC | Canceled post-market Expiry 2023.08.31 |
| 69768 | 2245668 | SANDOZ CYPROHEPTADINE (cyproheptadine hydrochloride 2 mg per 5 mL syrup) SANDOZ CANADA INCORPORATED | dormant 2023.08.01 |
| 73611 | 2251159 | T/GEL DAILY CONTROL 2 IN 1 (pyrithione zinc 1 % shampoo) JOHNSON & JOHNSON INC | Canceled post-market Expiry 2023.08.31 |
| 67836 | 2243895 | TAZORAC (tazarotene 0.1 % cutaneous cream) ALLERGAN INC | Canceled post-market Expiry 2023.08.31 |
| 90490 | 2420317 | VANCOMYCIN HYDROCHLORIDE FOR INJECTION, USP (vancomycin (vancomycin hydrochloride) 5 g per vial powder for solution for injection) JAMP PHARMA CORPORATION | dormant 2023.07.31 |

## **Exclusion List (on GitHub)**

The following changes have been made to the Exclusion List for the AUGUST 2023 Release Candidate. The list as it is on GitHub should be used.

Changes that have been made to the Blacklist are as follows:  
ACTION is either:

* STAY on Exclusion List
* ADD to Exclusion List
* REMOVE from Exclusion List

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **ntp\_code** | **ntp\_formal\_name** | **drug\_code** | **mp\_code** | **mp\_formal\_name** | **ACTION** |
| 63c8f110ed79d2e861bae01cb8891ce7 | cytarabine 100 mg and daunorubicin 44 mg powder for solution for injection | 100489 | 02515490 | VYXEOS (cytarabine 100 mg and daunorubicin 44 mg powder for solution for injection) JAZZ PHARMACEUTICALS IRELAND LIMITED | STAY |